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SUMMARY  
 Introduction : Patients with type 2 diabetes have an increased risk of chronic liver disease 
(CLD)  such as non-alcoholic fatty liver disease and steatohepatitis and about one third of 
cirrhotic patients have diabetes. However, the use of several antidiabetic agents may be a 
concern in case of hepatic impairment (HI).  
Area covered: An extensive literature search was performed to analyze the influence of HI on 
the pharmacokinetics (PK) of glucose-lowering agents and the potential consequences for 
clinical practice as far as the efficacy/safety balance of their use in diabetic patients with 
CLD.  
Expert Opinion : Almost no PK studies have been published regarding metformin, 
sulfonylureas, thiazolidinediones and alpha-glucosidase inhibitors in patients with HI. Only 
mild changes in PK of glinides, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose 
cotransporters type 2 (SGLT2) inhibitors were observed in dedicated PK studies in patients 
with various degrees of HI, presumably without major clinical relevance although large 
clinical experience is lacking. GLP-1 receptor agonists have a renal excretion rather than liver 
metabolism. Rare anecdotal case reports of hepatotoxicity have been described with various 
glucose-lowering agents contrasting with numerous reassuring data. Nevertheless, caution 
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 1. Introduction 
The liver is one of the principal organs involved in glucose metabolism. A link 
between diabetes and chronic liver disease (CLD) was first observed in the early half of the 
last century, and the complex and bi-directional relationship linking the liver and diabetes has 
recently gained intense new interest (Figure 1)  [1, 2]. Type 2 diabetes mellitus (T2DM) 
favors non-alcoholic fatty liver disease (NAFLD), both steatosis and non-alcoholic 
steatohepatitis (NASH) [3] while alcoholic cirrhosis, chronic hepatitis C virus and 
hemochromatosis are frequently associated with diabetes [4]. Overall, about 30% of patients 
with cirrhosis have diabetes.  Diabetes, which develops as a complication of cirrhosis, is 
known as "hepatogenous diabetes" [5]. An impaired response of the islet beta-cells of the 
pancreas and insulin resistance (both hepatic and muscular) are contributory factors to the 
development of diabetes in cirrhotic patients [6, 7]. Treatment of the diabetes is complex due 
to liver damage and potential hepatotoxicity of some oral hypoglycemic medications or drug-
associated adverse events favored by CLD [8]. 
Differential use of antidiabetic drugs in patients with co-morbid disease constellations 
will help to reduce treatment related complications and might improve prognosis [9]. 
However, guidelines fail to give advice on the use of specific glucose-lowering medications in 
patients with co-morbidity and the literature is deficient in studies documenting antidiabetic 
drug use in patients with CLD. Whereas several recent articles focused on the use of glucose-
lowering agents in patients with chronic kidney disease [10-12], only scarce review papers are 
available yet regarding the management of diabetic patients with CLD [13,14]. Furthermore, 
these papers focused on general management rather than on the specific use of glucose-
lowering agents and the place of new medications such as dipeptidyl peptidase (DPP-4) 
inhibitors (also known as gliptins), sodium glucose cotransporters type 2 (SGLT2) inhibitors 
and glucagon-like peptide-1 (GLP-1) receptor agonists was almost not considered [13].  
Managing diabetes in patients with CLD can be challenging because many 
antihyperglycemic therapies are contraindicated or must be used with caution for safety 
reasons [8]. Another interesting aspect concerns the use of insulin-sensitizing agents, well 
known compounds for the management of T2DM, in patients with NAFLD. Indeed, because 
insulin resistance seems to play a role in the development of NAFLD, the administration of 
insulin-sensitizing medications deserves much consideration in the management of patients 
with NAFLD, of course when T2DM is present but also in absence of diabetes [15, 16]. 
The aim of this review paper is to provide an updated analysis of the use of oral 
antidiabetic agents (OADs) and injectable agents in diabetic patients with CLD. After a brief 
description of how to assess liver function and evaluate the severity of hepatic impairment 
(HI), we will describe the PK characteristics as well as the safety profile of each glucose-
lowering compound in patients with various degrees of CLD.   
To identify relevant studies, an extensive literature search of MEDLINE was 
performed from 1970 to December 2013, with the names of the following pharmacological 
classes biguanides, sulfonylureas, meglitinides (glinides), alpha-glucosidase inhibitors, 
thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, human 
insulin or insulin analogs combined with any of the following terms : “chronic liver disease”, 
“hepatic impairment” or “cirrhosis”. Each generic name - metformin, glibenclamide 
(glyburide), glimepiride, glipizide, gliclazide, gliquidone, repaglinide, nateglinide, acarbose, 
miglitol, voglibose, pioglitazone, rosiglitazone, sitagliptin, vildagliptin, saxagliptin, 
linagliptin, alogliptin, dapagliflozin, canagliflozin, empagliflozin, exenatide, liraglutide, 
lixisenatide - was also combined with each of the various terms corresponding to CLD.  No 
language restrictions were imposed. Reference lists of original studies, narrative reviews and 
previous systematic reviews were also carefully examined. 
 
2. Classification of liver impairment 
Liver tests are commonly altered in patients with overweight/obesity and in patients 
with T2DM. The prevalence of NAFLD ranges 10-24% in the general population, reaching 
60-95% and 28-55% in obese and diabetic patients, respectively [17]. Although the etiology 
of NAFLD is still unclear, several lines of evidences have indicated a pathogenic role of 
insulin resistance in this disorder [3, 17]. Chronic inflammation associated to NASH may lead 
to progressive fibrosis. Cirrhosis is the ultimate stage of HI, whose severity may vary from 
patient to patient, and the management of diabetes in those patients is most often difficult.  
In hepatology, the Child-Pugh score, initially developed for selecting patients who 
may benefit from liver transplantation, is currently used to assess the overall prognosis of 
CLD, mainly cirrhosis [18]. In clinical pharmacology, it is used to score the severity of HI in 
order to guide the use of drugs in patients with CLD, although its limitations have been 
acknowledged [19]. The Child-Pugh score employs five clinical measures of liver disease : 
total bilirubin level, serum albumin concentration, prothrombin or international normalized 
ratio (INR) value, presence of ascitis and hepatic encephalopathy. Each measure is scored 
from 1 to 3, with 3 indicating most severe derangement. CLD is classified into Child-Pugh 
class A-C, employing the added score from above : 5-6 (class A = mild HI), 7-9 (class B = 
moderate HI) and 10-15 (class C : severe HI). Such classification has been used in the various 
PK studies with glucose-lowering agents described below. 
Noteworthy, hepatorenal syndrome is a distinctive complication of CLD and cirrhosis 
[20]. Therefore, renal function should be carefully monitored in all patients with cirrhosis and 
selection of antidiabetic pharmacotherapy should also take into account the possibility of 
associated renal impairment in such patients [10-12]. 
 
3. PK considerations 
PK studies are recommended in subjects with impaired hepatic function if hepatic 
metabolism accounts for a substantial portion of the absorbed drug [19]. Numerous glucose-
lowering drugs are excreted as parent drug or as active metabolite via the kidneys [12]. 
Nevertheless, HI may also interfere with the PK of various glucose-lowering medications. 
Considering the high prevalence of diabetes among patients with CLD and of hepatic 
disturbances among patients with T2DM, the analysis of PK changes of various glucose-
lowering agents in patients with HI should deserve careful evaluation. Pharmacodynamic 
(PD) effects in this population may also be of interest, although rarely evaluated. 
 
3.1. Biguanides (metformin) 
Metformin, a biguanide compound, is considered as the first-line drug for the 
treatment of T2DM [21]. Chemically, it is a hydrophilic base which exists at physiological pH 
as the cationic species. Consequently, its passive diffusion through cell membranes is very 
limited as well as liver metabolism. No metabolites or conjugates of metformin have been 
identified [22]. The absence of liver metabolism clearly differentiates the PK of metformin 
from that of other biguanides, such as phenformin (withdrawn from the market because of 
lactic acidosis). Metformin undergoes renal excretion. The elimination is prolonged in 
patients with renal impairment and correlates with creatinine clearance, even in patients with 
HI [23]. In contrast, liver impairment stricto sensu should not interfere with PK of metformin. 
However, no PK studies are available in patients with CLD. Recent experimental data in 
animals showed that metformin sinusoidal efflux from the liver is consistent with negligible 
biliary excretion and absence of enterohepatic cycling [24]. 
3.2. Sulfonylureas  
Sulfonylureas remain largely used in the management of T2DM [25] and are currently 
positioned as second-line after failure of metformin monotherapy [21]. They are associated 
with a higher risk of severe hypoglycemia, compared with metformin and more recent 
glucose-lowering therapies [26], especially in the elderly population and in patients with renal 
or liver disease.  Among the possible extra-pancreatic effects of sulfonylureas, a reduction of 
the hepatic extraction of insulin has been reported, which could contribute to increase 
peripheral insulin concentrations [25]. 
 Due to hepatic metabolism and renal excretion of the parent drug and/or active 
metabolites, sulfonylureas are classically contraindicated in patients with liver or kidney 
disease [27]. However, PK data on sulfonylureas are very limited in cirrhotic patients.  
 
3.2.1. Tolbutamide 
 The PK data after tolbutamide intravenous injection were compared in patients with 
cirrhosis (diagnosis made by clinical symptoms, liver function tests and laparoscopic 
examination, but without score of severity), in T2DM patients and in patients with renal 
impairment. The disappearance rate of tolbutamide from the blood was reduced in five of ten 
cases with cirrhosis. Prolonged half-lives (from about 4 hours in normal subjects to 7.8 to 
11.2 hours) were measured in those subjects although no significant correlation was observed 
with the results of liver function tests. No severe renal impairment was noticed in these 
patients. Reduction in arterial glucose concentrations tended to be greater and more prolonged 
in some cirrhotic patients. However, such changes in arterial blood glucose were not 
attributable to the prolongation of half-life of tolbutamide [28]. In another study in 10 subjects 
with HI, hepatic dysfunction did not necessarily cause a prolongation in the rate of 
metabolism of tolbutamide, but there was an apparent prolongation of the half-life for 
metabolism of tolbutamide when renal function was impaired [29]. No similar study has been 
published regarding chlorpropamide. Nevertheless, these limited observations led to 
recommendation of cautious use of first-generation sulfonylureas in patients with CLD 
because of a potential high risk of hypoglycemia [13, 14]. 
 
3.2.2. Glibenclamide (glyburide) 
 
Experimental results showed that human cytochrome P450 3A4 (CYP3A4) is the 
major enzyme involved in the in vitro metabolism of glibenclamide [30]. Glibenclamide is 
inactivated by the liver to 4-trans-hydroxyglibenclamide and 3-cis-hydroxyglibenclamide. 
Elimination of the drug appears to be evenly divided between biliary and renal routes [31]. 
Glibenclamide should not be prescribed for patients with severe CLD [32], although no 
specific PK studies in patients with HI are available in the literature.  
   
3.2.3. Glimepiride 
Glimepiride has fewer and less severe adverse effects than glibenclamide. It is 
metabolized by CYP2C9 and its PK is mainly unaltered in patients with liver disease [33].  In 
11 patients with CLD, the PK of glimepiride was similar to those of healthy volunteers [34]. 
Thus, whereas the PK characteristics of glimepiride are altered in T2DM subjects with renal 
disease [12], they may not be seriously affected in patients with CLD. However, data were 
obtained from patients with liver disease of unspecified severity and are, therefore, of limited 
clinical usefulness. Administration of glimepiride in diabetic patients with severe CLD is not 
recommended, as is the case for other sulfonylureas.  
 
3.2.4. Glipizide 
 The PK properties, spectrum and severity of side effects and metabolism of glipizide 
are somewhat different from those of first-generation sulfonylureas or even glibenclamide 
[35].  The hepatic metabolism of glipizide involves CYP2C9 and to a lesser extent CYP2C19. 
There are no data on PK of glipizide in patients with CLD. However, a study showed that 
glipizide significantly increased the estimated hepatic uptake of insulin in cirrhotic patients 
but not in other patients without CLD [36]. In absence of clear-cut data, caution is 
recommended when considering the use of glipizide in patients with CLD. 
 
3.2.1. Gliclazide 
Gliclazide is metabolized by the liver to inactive metabolites, which are eliminated 
mainly in the urine (80%). CYP2C9 is the major contributor to gliclazide metabolic clearance, 
although CYP2C19 may also be involved in hydroxymethyl metabolite of gliclazide 
formation (the major metabolic pathway) [37]. There are no data on PK of gliclazide in 
patients with CLD. In absence of specific data, gliclazide should also be used with caution in 
patients with CLD. 
 
3.2.5. Gliquidone 
Gliquidone is metabolized in the liver and has no renal excretion, in contrast to other 
sulfonylureas. Because accumulation does not take place in patients with renal impairment, 
this sulfonylurea may be used in patients with stable chronic kidney disease [38]. Because of 
its specific hepatic metabolism, its use should not be recommended in patients with CLD and 
no data are available in this population.  
 
3.3. Meglitinides (glinides) 
Compared to sulfonylureas, glinides are characterized by shorter half-lives as well as 
by the absence of significant renal excretion [39, 40]. These compounds are exposed to drug-
drug interactions via significant interferences on hepatic metabolism [41]. Despite they are 
metabolized in the liver, there are no large scale studies having assessed both the efficacy and 
safety of repaglinide and nateglinide in T2DM patients with CLD [39]. However, PK 
characteristics have been evaluated in patients with HI. The influence of HI on drug exposure 
and elimination appears to differ between repaglinide (significant interference) and 
nateglinide (only minimal change) (Table 1). The reason of this discrepancy remains 
speculative. However, the two meglitinide compounds are metabolized by different CYP 
isoforms, 2C8 for repaglinide [43] and 2C9 for nateglinide [40]. Furthermore,  
SLCO1B1 (organic anion-transporting polypeptide 1B1) polymorphism exerts different 
effects on the PK/PD of repaglinide (significant PK changes) and nateglinide (PK unaffected) 
[42]. The SLCO1B1*1B/*1B genotype is associated with reduced plasma concentrations of 
repaglinide, consistent with an enhanced hepatic uptake by OATP1B1, but has limited effects 
on the PK of nateglinide [43]. 
 
3.3.1. Repaglinide 
Repaglinide is metabolized mainly in the liver and is eliminated rapidly via the biliary 
route [44]. Its PK may therefore be altered by hepatic dysfunction. An open, parallel-group 
study compared the PK and tolerability of a single 4 mg dose of repaglinide in healthy 
subjects and patients with CLD (Table 1). Values for area under the concentration-time curve 
(AUC) and maximum plasma concentration (Cmax) were significantly higher in CLD patients 
compared with healthy subjects. Values for time to reach Cmax (tmax) did not differ between the 
groups, but terminal elimination half-life (t1/2) was significantly prolonged in CLD patients 
compared with previously determined values in healthy subjects. The mean residence time 
was prolonged in CLD patients compared to healthy subjects [5.9±4.4 versus 1.2±0.4 hours; 
geometric mean ratio or GMR : 4.7 (90% confidence interval or CI : 1.6-7.8); p=0.005]. AUC 
was inversely correlated with caffeine clearance in CLD patients but not in healthy subjects. 
Thus, repaglinide clearance is significantly reduced in patients with HI so that this glucose-
lowering agent should be used with caution in patients with CLD and is contraindicated in 
diabetic patients with severe HI [45].  
 
3.3.2. Nateglinide 
The clinical PK of nateglinide, a rapidly-absorbed, short-acting insulinotropic agent, 
has been extensively reviewed [40]. No significant PK alterations occur in patients with mild 
HI. A single-dose, open-label, parallel-group study compared the PK of 120 mg doses 
of nateglinide in subjects with cirrhosis and matched healthy subjects. In both groups, plasma 
concentration peaked in a median of 0.5 hours, and mean t1/2 values were comparable. 
However, exposure tended to be slightly increased (+ 30 % for AUC and + 37 % for Cmax) 
(Table 1). Mean apparent total clearance and mean renal clearance of nateglinide were 
comparable in both groups. Mean protein-bound fractions were also equivalent. No 
statistically significant or clinically relevant alterations in PK parameters 
of nateglinide resulted from hepatic dysfunction; therefore, adjustment of nateglinide dosage 
is not required in subjects with mild to moderate cirrhosis [46]. No data are available in 
patients with severe HI. 
Nateglinide was tested in a pilot 20-week study in diabetic patients with NASH who 
were randomly divided into two groups, 5 patients treated with nateglinide (90 mg before 
each meal, i.e. 270 mg/day) and 5 patients non-treated with nateglinide used as control group. 
Postprandial blood glucose, glycated hemoglobin (HbA1c), a 75-g oral glucose tolerance 
test, liver function, abdominal ultrasound and computerized tomography imaging tests 
and liver histological findings were all improved after treatment with nateglinide. This 




Mitiglinide is another rapid-acting insulin secretion-stimulating agent, which is approved 
in Japan for the treatment of T2DM [48].  Uridine diphosphate glucuronosyltransferase 
(UGT) isoforms UGT1A3 and UGT2B7 were found to be catalytic enzymes in mitiglinide 
carboxyl-glucuronidation in human liver [49] No PK study was specifically performed with 
mitiglinide in patients with CLD. 
 
3.4. Alpha-glucosidase inhibitors 
3.4.1. Acarbose 
Acarbose acts locally within the gastrointestinal tract and is characterized by a low 
systemic bioavailability [50]. Several results clearly documented the good tolerability and the 
absence of toxic effects of acarbose on liver, due to the lack of both intestinal absorption and 
hepatic metabolism of the drug at doses in the therapeutic range. Because of these 
characteristics, no PK studies are available with this compound in patients with CLD.  
However, several limited studies demonstrated the efficacy and safety of acarbose in diabetic 
patients with CLD [51], alcoholic cirrhosis [52], well-compensated non-alcoholic cirrhosis 
[53], and low-grade hepatic encephalopathy [54]. Acarbose has been also considered as a 
promising therapeutic strategy for the treatment of patients with NASH [55]. 
 
3.4.2. Miglitol and voglibose 
Miglitol is systemically absorbed but is not metabolized, and is rapidly eliminated by 
renal excretion as unchanged drug [56]. Voglibose is another alpha-glucosidase inhibitor 
commercialized in Japan. Only a minimal amount of drug is absorbed in unchanged form. 
One study reported that voglibose was an effective therapy for NASH in a patient with 
insufficient dietary and exercise therapy [57]. 
 
 
3.5. Thiazolidinediones  
Troglitazone was the first thiazolidinedione antidiabetic agent approved for clinical 
use in 1997 [58], but it was withdrawn from the market in 2000 due to serious idiosyncratic 
hepatocellular injury-type hepatotoxicity. Troglitazone contains the structure of a unique 
chroman ring of vitamin E, and this structure has the potential to undergo metabolic 
biotransformation to form quinone metabolites, phenoxy radical intermediate, and epoxide 
species [59]. Furthermore, troglitazone, unlike pioglitazone and rosiglitazone, induces the 
cytochrome P450 isoform 3A4, which is partly responsible for its metabolism, and may be 
prone to drug interactions [60]. The involvement of reactive metabolites in 
the troglitazone cytotoxicity has been proposed but still remains controversial [59]. 
Nevertheless, because troglitazone was withdrawn from the market because of hepatotoxicity, 
concern emerged about the use of other compounds of this pharmacological class in patients 
with CLD [60].  
 
3.5.1. Pioglitazone 
Pioglitazone and its active metabolites are excreted via the liver rather than the 
kidneys. It is metabolised mainly by CYP2C8 and to a lesser extent by CYP3A4 in vitro [61]. 
No study published the PK of pioglitazone in patients with CLD but some limited information 
could be found in the Food and Drug Administration report [62]. Compared with normal 
controls, subjects with impaired hepatic function (Child-Pugh class B/C) have an approximate 
45% reduction in pioglitazone mean peak concentrations but no change in the mean AUC 
values. In hepatic insufficiency, volume of distribution was increased, probably explaining 
why Cmax was reduced [63]. 
In a proof-of-concept study, the administration of pioglitazone, acting as an insuli-
sensitizer compound, led to metabolic and histologic improvement in subjects with NASH 
[64]. Further studies showed also favorable, although less convincing results, in NAFLD 
patients without diabetes [65]. Other findings suggest that long-term therapy with 
pioglitazone may be necessary to maintain improvements in disease activity in patients with 
NASH, although weight gain during treatment may ultimately limit its beneficial effects (see 
also section 4.5) [66]. 
3.5.2. Rosiglitazone 
Rosiglitazone is mainly metabolized by CYP2C8 into inactive metabolites, and < 1% 
of the parent drug appears in the urine in unchanged form [67]. No published study 
investigated the PK of rosiglitazone in patients with CLD but some data are available in the 
FDA report [68]. Unbound oral clearance of rosiglitazone was significantly lower in patients 
with moderate to severe liver disease (Child-Pugh class B/C) compared to healthy subjects. 
As a result, unbound Cmax and AUC∞ were increased 2- and 3-fold, respectively. Elimination 
half-life for rosiglitazone was about 2 hours longer in patients with CLD, compared to healthy 
subjects. Therefore, caution is required in patient with moderate HI and the drug should not be 
prescribed in patients with severe HI.  
In a study that compared the effects of rosiglitazone and metformin treatment, 
rosiglitazone but not metformin decreased liver fat, increased insulin clearance and 
augmented serum adiponectin concentrations (see also section 4.5) [69]. 
 
3.6. DPP-4  inhibitors  
DPP-4 inhibitors (gliptins) are a new class of OADs belonging to the incretin-based 
glucose-lowering agents. By inhibiting the inactivation of endogenous GLP-1, they improve 
glucose control without inducing hypoglycemia (in contrast to sulfonylureas) and are weight-
neutral [70]. Several molecules are already available, which are characterized by different PK 
properties [71, 72]. In contrast to previous glucose-lowering agents for which PK evaluation 
in patients with HI was almost absent (metformin, sulfonylureas) or scarce (repaglinide, 
nateglinide, glitazones), all five DPP-4 inhibitors already on the market were particularly well 
studied in patients with various degrees of HI as far as PK characteristics were concerned 
(Table 2). Furthermore, a recent intriguing paper suggests that DPP-4 may be a key player in 
CLD, a finding that may open new perspectives for the use of DPP-4 inhibitors in patients 
with CLD [73]. However, no clinical study with a chronic administration of a DPP-4 inhibitor 
in patients with CLD is available yet. 
   
3.6.1. Sitagliptin 
Sitagliptin is primarily excreted by renal elimination as unchanged drug, with only a 
small percentage (approximately 16%) undergoing hepatic metabolism. CYP3A4 has been 
shown to be the major cytochrome P450 isoenzyme responsible for the limited oxidative 
metabolism of sitagliptin, with some minor contribution from CYP2C8 [74]. The influence of 
moderate HI on the PK of sitagliptin should be minimal. In an open-label study, a single 100-
mg oral dose of sitagliptin was administered to patients with moderate CLD (Child-Pugh's 
scores ranged from 7 to 9) and healthy control subjects [75]. The mean AUC∞  and Cmax for 
sitagliptin were numerically, but not significantly, higher in patients with moderate HI 
compared with healthy matched control subjects (by 21% and 13%, respectively) (Table 2). 
These slight differences were not considered to be clinically meaningful. Furthermore, 
moderate HI had no statistically significant effect on the Tmax, apparent terminal t1/2 and renal 
clearance of sitagliptin. Thus, moderate HI has no clinically meaningful effect on the PK of 
sitagliptin [75]. 
The efficacy and safety of sitagliptin therapy has been shown in patients with diabetes 
complicated by NAFLD [76-78], NASH [79] or CLD caused by hepatitis C virus [80]. 
However, it has been also reported that NAFLD adversely affects the glycemic control 
afforded by sitagliptin [81]. 
 
3.6.2. Vildagliptin 
Vildagliptin is primarily metabolized via hydrolysis and the inactive metabolites are 
predominantly excreted by the kidneys [82]. An open-label, parallel-group study compared 
the PK of vildagliptin in patients with mild, moderate or severe CLD and in healthy subjects. 
All subjects received a single 100-mg oral dose of vildagliptin, and plasma concentrations 
of vildagliptin were measured up to 36 h post-dose. Exposure to vildagliptin (AUC∞ and Cmax) 
decreased non-significantly by 20 and 30%, respectively, in patients with mild HI. Exposure 
to vildagliptin was also decreased non-significantly in patients with moderate HI, by 8 and 23 
%, respectively. In patients with severe HI, Cmax was 6% lower than that in healthy subjects, 
whereas AUC∞ was numerically increased by 22% (Table 2). Because there was no 
significant difference in exposure to vildagliptin in patients with mild, moderate or severe HI, 




Saxagliptin is metabolized in vivo to form an active metabolite (2-fold less potent than 
its parent molecule), and both parent drug and metabolite are excreted primarily via the 
kidneys [59, 72]. Saxagliptin is largely metabolized by CYP3A4 and CYP3A5 isoforms. The 
PK of saxagliptin and its pharmacologically active metabolite, 5-hydroxy saxagliptin, were 
compared in nondiabetic subjects with mild, moderate or severe CLD and in healthy adult 
subjects in an open-label, parallel-group, single-dose (10 mg saxagliptin) study. As compared 
with healthy subjects, the AUC∞ values for saxagliptin were 10%, 38% and 77% higher in 
subjects with mild, moderate or severe HI, respectively (Table 2). The corresponding values 
were 22%, 7% and 33% lower, respectively, for 5-hydroxy saxagliptin, compared with 
matched healthy subjects. Saxagliptin Cmax values were 8% higher, 16 % higher and 6 % 
lower in patients with mild, moderate and severe HI, respectively, compared to controls 
(corresponding values for 5-hydroxy saxagliptin : -17%, -16% and -59%, respectively).  
According to these results, i.e. increase of saxagliptin exposure compensated for by a 
corresponding decrease of the exposure to its active metabolite, no dose adjustment is 
recommended for patients with any degree of HI [84]. 
 
3.6.4. Linagliptin 
In contrast to other DPP-4 inhibitors whose main route of elimination is the kidney 
[71, 72], the elimination of linagliptin is primarily non-renal [85]. Linagliptin undergoes 
enterohepatic cycling with a large majority (85%) of the absorbed dose eliminated in faeces 
via biliary excretion [72]. Therefore, a potential effect of HI on the PK of linagliptin may 
have important implications for dosing recommendations. This was the rationale for a 
multiple dose rather than a single dose study (as with other DPP-4 inhibitors described above) 
in patients with CLD.  
An open label, parallel group, study enrolled patients with mild, moderate or severe CLD 
and healthy subjects to investigate whether HI affects linagliptin PK, PD and tolerability [86]. 
Primary endpoints were linagliptin exposure following 5 mg linagliptin once daily for 7 days 
in patients with mild and moderate HI vs. healthy subjects or after a single 5 mg dose for 
patients with severe HI vs. healthy subjects. In patients with mild and moderate HI, steady-
state linagliptin exposure was slightly lower than in healthy subjects (Table 2). After a single 
dose, AUC(0,24 h) in patients with severe HI was similar to that in healthy subjects and Cmax 
tended to be lower (Table 2). Accumulation based on AUC or Cmax and renal excretion of 
unchanged linagliptin (≤ 7%) were comparable across groups. Median plasma DPP-4 
inhibition was similar in healthy subjects (91%), and patients with mild (90%) and moderate 
(89%) HI at steady-state trough concentrations, and in patients with severe HI 24 h after a 
single dose (84%). Thus, mild, moderate or severe HI did not result in any increase 
in linagliptin exposure after single and multiple dosing compared with normal hepatic 
function. The conclusion was that dose adjustment with linagliptin is not required in patients 
with HI [86].  
 
3.6.5. Alogliptin 
Alogliptin is metabolized into 2 identified minor metabolites: M-I, an N-demethylated 
active metabolite via CYP2D6, and M-II, an N-acetylated inactive metabolite. CYP3A4 may 
also be involved in the formation of other unidentified minor metabolites. Exposure to these 2 
metabolites in plasma, relative to unchanged drug, are <1% and <6%, respectively. 
Metabolism represents only a small part of the elimination of alogliptin, which is mainly 
excreted through the kidneys [71, 72]. 
After a single oral administration of 25 mg alogliptin, no clinical significant differences 
in AUC and Cmax exposure to the parent drug and its main metabolite M1 were observed in 
subjects with moderate HI (Child-Pugh 7-9) compared with healthy subjects. The elimination 
of both alogliptin and M1 was 2.5 hours longer in patients with moderate HI than in normal 
subjects. However, the magnitude of these increases was not considered clinically significant. 
Therefore, no dose adjustment is necessary for patients with mild to moderate HI (classes A 
and B)  [87]. However, these data were reported only as an abstract so that caution is 
recommended. Subjects with severe HI were not evaluated [87].  
   
 
3.7. SGLT2 inhibitors 
 SGLT2 inhibitors improve glycemic control in an insulin-independent fashion 
through inhibition of glucose reuptake in the kidney and offer a new option for the 
management of T2DM  A  recent review summarized the PK and toxicological characteristics 
of this novel pharmacological class [88]. 
 
3.7.1. Dapagliflozin 
Dapagliflozin is the SGLT2 inhibitor with the most clinical data available to date [89] 
and its PK properties have been extensively described in a recent review [90]. 
Dapagliflozin elimination is primarily via glucuronidation to an inactive main 
metabolite, dapagliflozin 3-O-glucuronide. An open-label, parallel-group study compared the 
PK of a single 10-mg oral dose of dapagliflozin in patients with various degrees of HI and in 
healthy control subjects. In those with mild, moderate, or severe HI, dapagliflozin mean Cmax 
values were 12% lower and 12% and 40% higher than healthy subjects, respectively. 
Mean dapagliflozin AUC∞ values were 3%, 36%, and 67% higher compared with healthy 
subjects, respectively (Table 3). These values were highly dependent on the calculated 
creatinine clearance of each group. Compared with healthy subjects, systemic exposure 
to dapagliflozin in subjects with CLD was correlated with the degree of HI. Due to the 
higher dapagliflozin exposures in patients with severe HI, the benefit:risk ratio should be 
individually assessed because the long-term safety profile and efficacy of dapagliflozin have 
not been specifically studied in this population [91]. Caution should be even greater when HI 
is combined with some degree of renal impairment [90]. 
 
3.7.2. Canagliflozin 
The PK and metabolism, the PD and the efficacy and safety of canagliflozin were 
recently reviewed [92].  One study (still unpublished) more specifically investigated the PK of 
canagliflozin in patients with CLD following administration of a single 300 mg dose of the 
drug. Relative to subjects with normal hepatic function, the geometric mean ratios for Cmax 
and AUC∞ of canagliflozin were 107% and 110%, respectively, in subjects with Child-Pugh 
class A (mild HI) and 96% and 111%, respectively, in subjects with Child-Pugh class B 
(moderate HI) (Table 3). These differences are not considered to be clinically meaningful. 
There is no clinical experience in patients with Child-Pugh class C (severe) HI [93]. 
 
3.7.3. Empagliflozin 
The PK/PD properties of empagliflozin have been recently reviewed [94]. The effect of 
HI on the PK of empagliflozin was investigated in an open-label, parallel-group study of 
subjects with mild, moderate, or severe HI and in matched controls with normal hepatic 
function who received a single dose of empagliflozin 50 mg [95]. Compared with subjects 
with normal hepatic function, exposure to empagliflozin (both Cmax and AUC∞) progressively 
increased with the severity of HI (Table 3) [95]. However, as the increase in empagliflozin 
exposure was less than two-fold in patients with impaired liver function, it was concluded that 
no dose adjustment of empagliflozin is required in these patients [95]. 
 
3.7.4. Ipragliflozin 
Ipragliflozin, a SGLT2 inhibitor in clinical development, is primarily eliminated via 
conjugation by the liver as five pharmacologically inactive metabolites. In an open-label, 
single-dose, parallel-group study, eight subjects with moderate HI [Child-Pugh score 7-9] and 
eight healthy, matched controls received a single oral dose of 100-mg ipragliflozin to evaluate 
the effect of moderate HI on the PK of ipragliflozin and its metabolites. Only a trend for a 
mild increased exposure was observed in patients with moderate HI versus controls (Table 3). 
No changes in elimination t1/2 and protein binding of ipragliflozin were observed in moderate 
HI subjects. Thus, moderate HI had no clinically relevant effects on the single-dose PK of 
ipragliflozin [96]. 
  
3.8. GLP-1 receptor agonists 
When oral therapy is not sufficient to control blood glucose, injectable agents may be 
used. Besides insulin therapy, GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide) 
offer new opportunities for the management of T2DM [21]. A recent review describes 
the PK and safety aspects of the currently available GLP-1 receptor agonists [97].  
 
3.8.1. Exenatide 
 The kidney appears to be the primary route of elimination and degradation 
of exenatide [98]. No PK studies have been done in patients with CLD; however, because 
exenatide is cleared primarily by the kidney, HI is not expected to affect blood levels and PD 
effects on glucose control. 
 
3.8.2. Liraglutide 
Liraglutide is metabolized in vitro by DPP-4 and neutral endopeptidase in a manner 
similar to that of native GLP-1, although at a much slower rate. The metabolite profiles 
suggest that both enzymes are also involved in the in vivo degradation of liraglutide. The lack 
of intact liraglutide excreted in urine and feces and the low levels of metabolites in plasma 
indicate that liraglutide is completely degraded within the body [99]. 
A parallel group, open label trial compared the PK of a single-dose (0.75 mg injected 
subcutaneously) of liraglutide in four groups of six subjects with healthy, mild, moderate and 
severe HI, respectively [100]. Exposure to liraglutide was not increased by HI. On the 
contrary, mean AUC∞ was highest for healthy subjects and lowest for subjects with severe HI 
(severe/healthy: 0.56, with 90% CI 0.39, 0.81). Cmax also tended to decrease with HI 
(severe/healthy: 0.71, with 90% CI 0.52, 0.97), but tmax was similar across groups (11.3-13.2 
h). According to the authors, because the half-life of liraglutide was not affected by HI, the 
differences in the overall exposure (AUC∞) of liraglutide might result primarily from 
differences in absorption of the drug from the subcutaneous depot rather than differences in 
its subsequent metabolism. Nevertheless, because the vast majority of liraglutide molecules 
are reversibly bound to plasma albumin, a decrease in albumin concentration as seen in 
patients with severe CLD may also result in an increased rate of metabolism of liraglutide by 
various enzymes. However, this PK effect, resulting in lower plasma levels, might be 
compensated for by a possible enhanced PD effect in the setting of reduced circulating 
albumin concentrations that leads to an increased free fraction of liraglutide able to interact 
with GLP-1 receptors. Because of these diverse effects, data are not conclusive to suggest a 
dose increase of liraglutide. Thus, the results indicate that patients with T2DM and CLD can 
use standard treatment regimens of liraglutide. There is, however, currently limited clinical 
experience with liraglutide in patients with HI [100]. 
 
In a Japanese study, the effectiveness of liraglutide in NAFLD patients with T2DM 
was compared to sitagliptin and pioglitazone. Administration of liraglutide improved T2DM 
but also resulted in improvement of liver inflammation, alteration of liver fibrosis, and 
reduction of body weight and compared favorably with sitagliptin and pioglitazone [101]. In a 
case report, a patient who had suffered from T2DM and from concomitant cryptogenic 
cirrhosis was treated with liraglutide, obtaining an optimal metabolic control associated with 
an improved clinical condition for the cirrhosis [102]. Because of these preliminary promising 
results, LEAN (“Liraglutide Efficacy and Action in NASH”), a phase II, multicentre, double-
blinded, placebo-controlled, randomized clinical trial, has been designed to investigate 
whether a 48-week treatment with 1.8 mg liraglutide will result in improvements in liver 
histology in patients with NASH [103]. The results are not available yet. 
 
3.8.3. Lixisenatide 
The elimination of lixisenatide is expected to follow that of endogenous peptides with 
renal filtration followed by tubular reabsorption and subsequent metabolic catabolism. 
The influence of HI on lixisenatide PK has not been evaluated. No dose adjustment is 
needed in patients with HI as hepatic dysfunction is not expected to affect the PK of 
lixisenatide [104].  
 
3.9. Other glucose-lowering agents 
Some other glucose-lowering agents are only approved in the US : bile acid 
sequestrants (colesevelam), bromocriptine and pramlintide. Because these drugs are either not 
absorbed or not investigated in patients with CLD, they will not be considered in the present 
review. 
 
3.10. Insulin and insulin analogs 
To study the mechanisms of glucose intolerance and hyperinsulinism in cirrhosis, our 
group compared the plasma glucose, insulin, and C-peptide levels during a frequently 
sampled intravenous glucose tolerance test in 9 compensated cirrhotic patients and 9 matched 
healthy volunteers. Cirrhosis was characterized by an important peripheral hyperinsulinism, 
resulting from both a higher insulin secretion rate and a markedly reduced insulin hepatic 
clearance [105]. Portosystemic/intrahepatic shunting may also play a role in some cirrhotic 
patients [6]. When exogenous insulin is necessary, the daily dose required to control blood 
glucose is difficult to predict because of the opposite influence of various factors. In patients 
with decompensated liver disease, the requirement may be decreased due to reduced capacity 
for gluconeogenesis, resulting in lower hepatic glucose output, and reduced hepatic 
breakdown of insulin. However, patients with impaired hepatic function may also have an 
increased need for insulin to compensate for insulin resistance [14]. 
Exogenous insulin uptake by the human cirrhotic liver was studied in 6 patients with 
Laennec's cirrhosis, and the result was compared with that found in 10 control patients with 
varying diseases affecting the biliary system. The fractional hepatic extraction of insulin was 
only 13±5% in cirrhotic patients and differed significantly from the fractional hepatic 
extraction found in controls (51±5%; P<0.001) [106].  
Insulin therapy can be used at any stage of HI, although clinical studies are scarce in 
insulin-treated diabetic patients with CLD [13, 14]. In a small case series of four cirrhotic 
patients with T2DM and inadequate blood glucose control with conventional insulin therapy, 
initiation of continuous subcutaneous insulin infusion with a portable pump was beneficial in 
controlling blood glucose values [107]. There is no single study reporting extensive 
experience with insulin analogs in patients with CLD. 
4. Toxicological considerations 
Many patients with T2DM are treated by several medications, not only glucose-lowering 
agents, but also pharmacological compounds to manage comorbidities such as hypertension, 
dyslipidemia and cardiovascular diseases [108].  In case of the occurrence of hepatic 
disturbances in a patient with T2DM, and after exclusion of a viral or metabolic origin, it may 
not be easy to decide which drug might be responsible for hepatotoxicity. Furthermore, while 
some medications have predictable hepatotoxicity, many more have associated idiosyncratic 
reactions [109]. To our knowledge, there is no obvious information supporting a greater risk 
of severe hepatotoxicity in diabetic patients with mild liver disturbances (NAFLD) receiving 
any type of glucose-lowering agents. 
4.1.Metformin 
The use of metformin has been limited in many diabetic patients considered as at risk 
of complications, especially lactic acidosis [110]. Manufacturer prescribing information and 
some current literature caution against metformin use in patients with CLD [111]. This 
recommendation is interpreted variably by different prescribers, with some believing that the 
caution implies metformin can cause or worsen liver injury [112] and others rather believing 
that liver disease predisposes patients to developing lactic acidosis [113]. Metformin does not 
appear to cause or exacerbate liver injury and, indeed, may be beneficial in patients with 
NAFLD [17, 114]. NAFLD frequently presents with transaminase elevations (alanine 
aminotransferase or ALT) but should not be considered a contraindication to metformin use. 
The liver appears to be a key organ not only for the antidiabetic effect of metformin but also 
for the development of lactic acidosis [115]. Literature evidence of liver disease being 
implicated with metformin-associated metabolic acidosis is largely represented by case 
reports [113, 115]. Most such patients had cirrhosis, with some degree of renal impairment. 
For this reason, it seems reasonable to use metformin with caution in patients with moderate 
CLD and to avoid its use in patients with severe CLD (Table 4). Furthermore, identifying 
patients with cirrhosis and controlling renal function before initiating metformin seem prudent 
[111]. Any circumstance favoring dehydration should promote the interruption of metformin, 
especially in such fragile patients [113].  
Finally, and interestingly, metformin therapy is associated with a reduced risk of 
hepatocellular carcinoma [116], especially in patients with hepatitis C virus [117], and seems 
to have a protective effect on hepatocellular carcinoma progression [118] and liver-related 
death or need for hepatic transplantation [119]. Further long-term, randomized controlled 
trials are needed to adequately assess the safety and efficacy of metformin therapy in patients 
with comorbid diabetes and chronic hepatitis C virus [117]. 
 
4.2.Sulfonylureas 
Although the major risk associated with sulfonylureas is hypoglycemia and this risk is 
known to be increased in more fragile patients, no such observations were specifically 
described in patients with CLD in contrast to what has been reported in patients with chronic 
kidney disease [12]. Poor nutrition can be an issue in patients with CLD, which may have an 
impact on the development of hypoglycemia. Patients who are not abstinent from alcohol 
should be very cautious when taking sulfonylureas, because alcohol increases the risk of 
hypoglycemia by inhibiting hepatic gluconeogenesis. 
Drug-induced hepatotoxicity has been reported infrequently with various sulfonylureas 
used as glucose-lowering agents for the management of T2DM : chlorpropamide [120], 




As with sulfonylureas, rare case reports of hepatotoxicity associated with repaglinide 
have been reproted, either acute hepatotoxicity [128] or cholestatic hepatitis [129]. 
4.4.Alpha-glucosidase inhibitors 
Acarbose has been used safely in patients with CLD in one clinical trial, although the 
risk of hyperammonemia was increased [51]. A case report described a patient with possible 
acarbose-induced hepatotoxicity and compared other reported cases from the literature [130]. 
Another case of hepatotoxicity has been reported with migitol [131] as well a case of hepatic 
necrosis with cholestasis associated with long-term voglibose administration [132]. 
 
4.5.Thiazolidinediones 
Troglitazone was the first thiazolidinedione antidiabetic agent approved for clinical 
use, but it was rapidly withdrawn from the market due to serious idiosyncratic hepatotoxicity, 
as already discussed [59]. Clinical evidence supports the conclusion that rosiglitazone and 
pioglitazone do not share the hepatotoxic profile of troglitazone [60]. In a randomized, 3-year, 
double-blind, hepatic safety study in the US in which 2,097 patients with T2DM received 
either pioglitazone or glibenclamide (glyburide), the hepatic safety profile of pioglitazone was 
similar to that of glibenclamide in long-term use in patients with poorly controlled T2DM 
[133].No evidence of hepatotoxic effects was observed in studies that involved 5,006 patients 
taking rosiglitazone as monotherapy or combination therapy for 5,508 person-years [134]. All 
together, these findings suggest that the idiosyncratic liver toxicity observed with troglitazone 
is unlikely to be a thiazolidinedione or a PPAR-gamma agonist class effect [60]. On the 
contrary, poorly controlled patients with T2DM may have moderate elevations of serum ALT 
(reflecting NAFLD) that will decrease with improved glycemic control during treatment with 
pioglitazone or rosiglitazone. These results are in agreement with the favorable effects of 
glitazones initially reported in patients with NAFLD [64, 65], although less convincing results 
were reported afterwards. These positive results may be at least partly explained by the 
glitazone-induced increase in adiponectin, which exerts an important metabolic role at the 
level of the liver and seems critical to reverse insulin resistance and improve liver histology in 
NASH patients [135]. It has been suggested that thiazolidinediones may in the future be 
increasingly used in patients with NASH [136].  However, so far there is no proof that any 
oral antidiabetic agent helps patients with NASH by a direct hepatic effect in the long run. 
Two randomized placebo-controlled trials investigated the effects of pioglitazone in 
patients with insulin resistance and hepatitis C treated with peginterferon-alpha-2b and 
ribarivin and reported contrasted results. In patients with chronic hepatitis C genotype 4, a 
combination of pioglitazone, peginterferon-alpha-2b and ribavirin increased virological 
response and decreased insulin resistance, compared with patients not receiving pioglitazone, 
without an increase in adverse events [137]. However, in another study in patients with  
insulin resistance and chronic hepatitis C genotype 1, treatment with pioglitazone before and 
during treatment with peginterferon alpha-2a plus ribavirin improved several indices of 
glycemic control, but did not improve virologic response rates compared with peginterferon 
alpha-2a plus ribavirin alone [138]. 
According to the official labeling, pioglitazone should not be prescribed to patients 
suffering from liver disease or in case of an increase in alanine aminotransferase (ALT) 
enzyme 2.5 times above the limit. If liver enzymes increase and continue to stay high (2.5 
times the upper limit of normal) after administration of pioglitazone, it is usually an obvious 
sign of liver damage. If the ALT test shows that the enzyme level is 3 times higher than the 
norm, the reanalysis should be undergone as quickly as possible. In case the second test 
reveals the same high level of enzymes, pioglitazone should be immediately discontinued. 
4.6.DPP-4 inhibitors 
The overall safety profile of DPP-4 inhibitors is generally good, even if some concern 
about possible exocrine pancreatic alterations have been reported [139]. Especially, no 
hepatotoxicity has been reported in large clinical trials. This has been shown in a pooled 
analysis of 25 clinical studies and 14,611 patients (n = 7,726 : sitagliptin group; n = 6,885 : 
non-exposed group) for sitagliptin [140] and in a similar pooled analysis of 38 studies 
with vildagliptin (> 7000 subject-years of exposure to vildagliptin 50 mg bid and > 6500 
subject-years of exposure to all comparators). For mild hepatic enzyme elevations with and 
without elevated bilirubin levels, the odds ratio for vildagliptin 50 mg bid were 1.24 (95% CI: 
[0.80, 1.93]) and 1.19 (95% CI: [0.29, 4.90]), respectively. The exposure-adjusted incidences 
of markedly elevated hepatic enzymes and for enzyme elevations with bilirubin ≥2 times the 
upper limit of normal with vildagliptin were similar or lower than those in the all comparator 
group. For hepatic-related adverse events, the odds ratio for vildagliptin was 0.87 (95% CI: 
[0.64, 1.19]) [141]. These data were confirmed in another pooled analysis showing 
that vildagliptin was overall well tolerated in clinical trials of up to >2 years in duration [142]. 
Reassuring hepatic safety data have also been reported with saxagliptin [143] and linagliptin 
[144]. In a systematic review and meta-analysis about the longer term safety of DPP-4 
inhibitors in patients with T2DM, hepatotoxicity was not considered as a concern [139]. 
Nevertheless, a few cases of drug-induced hepatic injury associated with sitagliptin [145] or 
of elevated hepatic enzymes potentially associated with sitagliptin [146] have been reported. 
The causal relationship remains, however, uncertain because of the complex medical history 
of many case reports. 
In the only study where a DPP-4 inhibitor (5 mg linagliptin) was administered once 
daily for 7 days in patients with mild and moderate HI, the DPP-4 inhibitor was well tolerated 
[86]. 
4.7.SGLT-2 inhibitors 
  Available data from large phase II-III trials showed that dapagliflozin [147], 
canagliflozin [148] and empagliflozin [94] do not cause hepatotoxicity. No case reports 
describing alterations of liver tests with SGLT-2 inhibitors have been reported so far.    
4.8.GLP-1 receptor agonists 
An interim analysis of data from the open-label, uncontrolled extension of three 
double-blind, placebo-controlled trials examined the metabolic effects of 2 years of exenatide 
treatment in patients with T2DM. Patients with normal baseline ALT had no significant ALT 
change. However, patients with elevated ALT at baseline had a slight but significant reduction 
of ALT from baseline and 39% achieved normal ALT by week 104 [149]. A trial was 
specifically designed to investigate the effects of exenatide on liver biochemistry, liver 
histology and lipid metabolism in patients with NAFLD (ClinicalTrials.gov Identifier: 
NCT00529204), but the results are not available yet. Individual patient data meta-analysis of 
the LEAD program showed that a 26-week therapy with liraglutide 1.8 mg is safe, well 
tolerated and improves liver enzymes in patients with T2DM. This effect appears to be 
mediated by its favorable action on weight loss and glycemic control [150]. No such specific 
analysis has been performed yet with lixisenatide, but no liver safety concern has been 
reported with this new GLP-1 receptor agonist [151]. 
 
4.9.Insulin and insulin analogs 
Insulin can be used in patients with all stages of CLD and does not exert hepatotoxic 
effects. However, the dose of insulin required in cirrhotic patients for optimal glucose control 
without hypoglycemia should be carefully adjusted upon an individual basis and blood 
glucose monitoring. 
5. Conclusion 
The increasing prevalence of patients with T2DM and CLD, especially among obese 
individuals, requires appropriate selection and dosing of glucose-lowering agents (Table 4). 
Old antidiabetic drugs (metformin, sulfonylureas) were poorly investigated in patients with HI 
so that their use is classically contraindicated in patients with moderate to severe HI because 
of a possible higher risk of lactic acidosis (with metformin) and of hypoglycemia (with 
sulfonylureas). Glitazones were also poorly studied in this population after the withdrawal of 
troglitazone because of hepatotoxicity and should be used with caution even if pioglitazone 
and rosiglitazone are not hepatotoxic. Better PK data have been published specifically in 
patients with various degrees of HI with glinides, DPP-4 inhibitors and SGLT-2 inhibitors and 
overall the results were almost reassuring, with some limited PK changes probably without 
clinical relevance in most cases. A benefit/risk balance should be considered when prescribing 
a glucose-lowering medication in diabetic patients with CLD. Whereas NAFLD is generally 
improved by the use of glucose-lowering agents, via a better glucose control especially when 
insulin resistance is reduced, the problem of controlling effectively and safely blood glucose 
becomes more crucial in patients with advanced cirrhosis.    
 
EXPERT OPINION SECTION 
Type 2 diabetes mellitus (T2DM) and chronic liver disease (CLD) are common long-
term conditions in our modern society and the two conditions often coexist. There are strong 
arguments to support a bidirectional relationship : diabetes predisposes to liver disease and 
conversely liver disease  predisposes to diabetes (“hepatogenous diabetes”). Furthermore, 
there is evidence to suggest that diabetes can have a significant adverse effect on patients with 
CLD, leading to increased complications and premature mortality. While type 2 diabetes, 
nonalcoholic fatty liver disease (NAFLD), steatosis and nonalcoholic steatohepatitis (NASH), 
appears to have common origins related to abdominal obesity and insulin 
resistance, diabetes is also common among patients with alcoholic and viral CLD. 
In patients with NAFLD and NASH, improvement in metabolic indices, with lifestyle changes 
but also via pharmacological approaches, appears to reduce the progression of CLD. 
Interestingly this effect seems more favorable with insulin-sensitizing agents than with 
strategies increasing insulin concentrations, although more recent studies with 
thiazolidinediones were more disappointing than initially reported observations. However, it 
is not clear whether improving glycemic control in other more advanced forms of CLD, 
especially cirrhosis, also leads to improved clinical outcomes and overall prognosis.  
Managing diabetes in patients with CLD can be challenging because many glucose-
lowering therapies are contraindicated or must be used with care. However, such precautions 
generally result from the fear of complications (as lactic acidosis with metformin and 
hypoglycemia with sulfonylureas) rather than from well-documented observations from 
controlled clinical studies. Indeed, only a paucity of data are available in the literature 
regarding the PK characteristics, the efficacy and the safety of commonly prescribed glucose-
lowering agents such as metformin, sulfonylureas, alpha-glucosidase inhibitors (acarbose) and 
thiazolidinediones (pioglitazone and rosiglitazone) in diabetic patients with CLD. A few case 
reports have been published about a possible hepatotoxicity of some of these compounds but 
the causal relationship remains doubtful in most instances. Metformin may be useful 
in patients with NAFLD (detected by mild to moderate increases in transaminase liver 
enzymes), and even might reduce the progression to and the severity of hepatocellular 
carcinoma. However, in case of advanced cirrhosis, caution is recommended, especially 
because the possibility of associated renal impairment and reduced tissue perfusion that could 
favor lactic acidosis. Pioglitazone, a well-known insulin sensitizer, has been shown to have 
the capacity to reduce fatty liver, at least in some studies, but its use in more advanced stages 
of CLD is not documented.  
Sulfonylureas and insulin must be used with caution in patients with advanced CLD, 
as hypoglycemia may be a concern. In diabetic patients with moderate to severe stages of 
cirrhosis, it is probably prudent not to use sulfonylureas, and insulin doses must be carefully 
adjusted according to results of blood glucose monitoring in those patients. Glinides may 
represent an alternative to sulfonylureas, with a preference for nateglinide compared to 
repaglinide.  
Newer antihyperglycemic agents have not been widely used in diabetic patients with 
CLD. Nevertheless, the recent literature offers more detailed specific PK studies with these 
medications in patients with various degrees of HI than the scarce data (if any) available with 
older compounds. No clinically relevant increase in systematic exposure to DPP-4 inhibitors 
(gliptins) has been reported so that no dose reduction is recommended in patients with HI, 
including with linagliptin whose specific hepatic metabolism is well known. This contrasts 
with the reduction of the daily dose according to the glomerular filtration rate in patients with 
chronic kidney disease (for sitagliptin, vildagliptin, saxagliptin and alogliptin, characterizd by 
renal elimination). Another advantage of DPP-4 inhibitors compared to sulfonylureas is the 
very limited risk of hypoglycemia. Similar favorable PK results were reported with GLP-1 
receptor agonists, especially liraglutide, in patients with various degrees of HI, and liraglutide 
has been also shown to improve liver prognosis of patients with NAFLD. No signs of 
hepatotoxicity have been reported so far with incretin-based therapies, contrasting with some 
concern and controversy regarding exocrine pancreas. 
Only limited data have been published regarding the use of SGLT2 inhibitors in 
diabetic patients with CLD. Available PK data suggested an increase in exposure to 
dapagliflozin, canagliflozin and empagliflozin in patients with mild to severe HI. Because the 
increase was less than two-fold, no dose reduction is recommended. However, caution is 
necessary in absence of larger clinical studies in such a fragile population with advanced 
CLD. 
Finally, since CLD patients are commonly treated with multiple-drugs, the drug-drug 
interactions in diabetic patients with CLD are important considerations in selecting the most 
appropriate glucose-lowering medications. 
In conclusion, the management of patients with diabetes and CLD represents a 
challenge for the clinician. Clinical success may be enhanced by selecting the most 
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- Diabetes predisposes to chronic liver disease (CLD), especially non-alcoholic fatty liver 
disease that may progress to non-alcoholic steatohepatitis and cirrhosis. 
- CLD, especially cirrhosis, predisposes to diabetes, which may require specific therapy 
for appropriate glucose control. 
- Besides kidneys, liver contributes to the elimination of several glucose-lowering agents 
and CLD may render more difficult the management of diabetes. 
- Overall, the influence of CLD on PK/PD of glucose-lowering agents is less well 
documented in the literature than the influence of chronic kidney disease. 
- Almost no specific PK studies with classical antidiabetic agents (metformin, 
sulfonylureas, glitazones, alpha-glucosidase inhibitors) have been published in subjects 
with hepatic impairment (HI).  
- Metformin, which is not metabolized but excreted unchanged by the kidneys, can be used 
in patients with HI and may exert various favourable effects. 
- Caution is recommended with the use of sulfonylureas in absence of well-documented 
studies in patients with CLD and because of a potential higher risk of hypoglycemia. 
- Specific PK studies in patients with HI showed no clinically relevant changes in exposure 
to DPP-4 inhibitors and liraglutide, arguing for no need of dose adjustment (in contrast to 
the reduction recommended in case of renal impairment).  
- Specific PK studies in patients with HI have been performed with SGLT2 inhibitors. 
Only limited increase in overall exposure was observed, presumably without clinical 
relevance. 
- Considering the increasing prevalence of patients combining CLD or HI and diabetes, 
there is a crucial need for more clinical studies to evaluate the efficacy/safety balance of 
the various available glucose-lowering strategies in this special population.  
 
 
Figure 1 : Illustration of the two-way relationship between diabetes and chronic liver disease. 
T2DM : type 2 diabetes mellitus. NAFLD : non-alcoholic fatty liver disease (steatosis). 
NASH : non alcoholic steatohepatitis.  
Table 1 : PK characteristics of repaglinide and nateglinide in healthy subjects and patients 
with chronic liver disease (CLD).  
 Healthy 
subjects 
CLD patients GMR (90% CI) P value 
Repaglinide [45]  









91.6 ± 67.0 
46.7 ± 24.3 
0.8 (0.5-1.1) 
0.8 ± 0.2 
(Child-Pugh : 7 to 
< 11 points) 
12  
368.9 ± 233.4 
105.4 ± 31.6 
0.8 (0.5-1.0) 















Nateglinide [46]  











5620 ± 1310 
0.5 (0.5-2.0) 
2.91 ± 1.84 
(Child-Pugh :  ≥5 
to ≤11 points) 
8  
18,470 ± 7510 
7700 ± 4890 
0.5 (0.5-0.75) 














Results are expressed as mean ± SD  (except for Tmax : median, range) and by geometric mean 
ratio (GMR) CLD/healthy subjects function (90% confidence intervals). NA : data not 
available. NS : not statistically significant. Cmax : maximum plasma concentration. AUC : area 
under the concentration-time curve. Tmax : time to reach Cmax. T1/2 : terminal elimination half-
life. 
Table 2 : Drug exposure of DPP-4 inhibitors in subjects with various degrees of chronic liver 
disease (CLD) (according to Child-Pugh staging) compared with subjects with normal liver 
function.  
 Reference Exposure Mild CLD 
GMR (90% CI) 
Moderate CLD  
GMR (90% CI) 
Severe CLD 
GMR (90% CI) 
Sitagliptin 
(single dose 














of 100 mg) 




0.70 (0.46- 1.05) 
0.80 (0.60-1.06) 










Cmax 1.077  
(0.763, 1.519) 
1.016 
 (0.720, 1.432) 
0.941 
 (0.667, 1.328) 
 
AUC∞ 1.097  
(0.828, 1.453) 
1.383 
 (1.044, 1.832) 
1.767 





Cmax 0.83 (NA) 0.84 (NA) 0.41 (NA) 
AUC∞ 0.78 (NA) 0.93 (NA) 0.67 (NA) 
Linagliptin 
(5 mg once 
daily for 7 
days) (*) 
Graefe-







92.3 (62.8- 135.6) 
85.5 (70.2- 104.2)  
 
77.0 (44.9-132.3) 












92 (NA, NS) 
90 (NA, NS) 
NA 
NA 
 Results are expressed as % changes versus subjects with normal liver function or as geometric 
mean ratio (GMR) CLD/healthy subjects function (90% confidence intervals). NA : data not 
available. NS : not statistically significant. Cmax : maximum plasma concentration. AUC∞ : 
area under the concentration-time curve from zero to infinity (*) : Single dose of 5 mg in 
patients with severe HI. 
Table 3 : Drug exposure of SGLT-2 inhibitors in subjects with various degrees of chronic 
liver disease (CLD) (according to Child-Pugh staging) compared with subjects with normal 
liver function.  
 
 Reference Exposure Mild CLD 
GMR (90% 
CI) 
Moderate CLD  
GMR (90% CI) 
Severe CLD 
GMR (90% CI) 
Dapagliflozin 















167 (124-232) (*) 
Canagliflozin 


















































Results are expressed as % changes versus subjects with normal liver function or as geometric 
mean ratio (GMR) CLD/healthy subjects function (90% confidence intervals). NA : data not 
available. Cmax : maximum plasma concentration. AUC∞ : area under the concentration-time 
curve from zero to infinity. (*) : 90% CI derived from data shown graphically. 
Table 4 : Clinical practice recommendations regarding the use of glucose-lowering agents in 
diabetic patients with various degrees of hepatic impairment (HI). Please note that the 
reported experience with any of these pharmacological classes is very limited and the absence 
of official guidelines; therefore caution and careful clinical supervision are recommended in 










Feared adverse event 
Biguanides 








Lactic acidosis (***) 
Sulfonylureas 



















































Hepatotoxicity ( ?) 
DPP-4 inhibitors 




















Unknown (but no 
clinical experience) 
GLP-1 receptor agonists 











Unknown (but no 
clinical experience) 




(*) Favorable effects on NAFLD (steatosis and NASH) and possible protective effects against 
hepatocelluar carcinoma 
(**) Favorable effects on NAFLD (steatosis and NASH) and liver inflammation 
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